Evidence map›Paper›PMID 41833362›Full record

ArticlemAbs2026

Impact of process parameters on IgG glycosylation in CHO systems: a comprehensive quantitative analysis.

Javier Bravo-Venegas, Jose Rodriguez-Siza, Mauricio Vergara, Mauro Torres, Alan Dickson, Jorge R Toledo, María Carmen Molina, Marcela A Hermoso, Julio Berríos, Claudia Altamirano

Abstract read
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Javier Bravo-VenegasDepartment of Chemical Engineering, University of Manchester, Manchester, UK.
Jose Rodriguez-SizaSchool of Biochemical Engineering, Faculty of Engineering, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
Mauricio VergaraSchool of Biochemical Engineering, Faculty of Engineering, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
Mauro TorresDepartment of Chemical Engineering, University of Manchester, Manchester, UK.
Alan DicksonDepartment of Chemical Engineering, University of Manchester, Manchester, UK.
Jorge R ToledoLaboratorio de biotecnología y Biofarmacia, Departamento de Fisiopatología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
María Carmen MolinaLaboratorio de anticuerpos recombinates e inmuno-oncologia, Núcleo Interdisciplinario de Farmacología e Inmunología (NIFI), Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Marcela A HermosoImmunology Programme, Faculty of Medicine, University of Chile, Santiago, Chile.
Julio BerríosSchool of Biochemical Engineering, Faculty of Engineering, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
Claudia AltamiranoSchool of Biochemical Engineering, Faculty of Engineering, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.ORCID 0000-0002-6389-086X

Funding

ANID Scholarship 21212223ANID Scholarship 21232083Biotechnology and Biological Sciences Research Council of the UK BB/N004192/1National Research and Development Agency of Chile ANID FONDEQUIP EQM 240055National Research and Development Agency of Chile ANILLO C&T ACT210068National Research and Development Agency of Chile FONDECYT 1221031National Research and Development Agency of Chile FONDECYT 1241453National Research and Development Agency of Chile FONDEF ID23I10018National Research and Development Agency of Chile FOVI22005National Research and Development Agency of Chile FOVI240154
6 · The paper itself

Abstract

Controlling glycosylation, a critical quality attribute of biopharmaceuticals such as monoclonal antibodies, is essential, as it significantly influences biological activity and therapeutic efficacy. Although numerous studies have examined the impact of process parameters (PP, e.g. temperature, pH, dissolved oxygen) on glycosylation, the lack of standardized reporting makes cross-study comparisons challenging and prevents clear conclusions. Here, we systematically reviewed the literature and applied a normalized quantitative framework, the Glycan Indices approach, as a standardized quantitative criterion to evaluate the impact of process parameters on glycoform distribution in IgG-producing CHO cell systems objectively. This methodology enabled the integration and reinterpretation of large, heterogeneous datasets, validating some well-known patterns while providing novel perspectives about process parameters. Our analysis revealed that PP manipulations of pH, dissolved oxygen or CO

Indexed as

Antibodies, MonoclonalImmunoglobulin GAnimalsCHO CellsCricetinaeCricetulusGlycosylationHumansHydrogen-Ion ConcentrationPolysaccharidesTemperatureAntibodies, MonoclonalImmunoglobulin GPolysaccharidesbioprocess optimizationCHO cellscritical quality attributes (CQA)culture conditionsglycan distributionglycan indicesMonoclonal antibodiesquantitative analysissystematic reviewtherapeutic efficacy

Identifiers

PMID41833362
PMCPMC12990948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.